Privium Fund Management B.V. Purchases 43,820 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Privium Fund Management B.V. increased its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 17.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 294,800 shares of the biotechnology company's stock after purchasing an additional 43,820 shares during the quarter. Rocket Pharmaceuticals makes up 1.4% of Privium Fund Management B.V.'s portfolio, making the stock its 21st biggest position. Privium Fund Management B.V. owned 0.32% of Rocket Pharmaceuticals worth $5,445,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its stake in shares of Rocket Pharmaceuticals by 174.3% during the first quarter. Janus Henderson Group PLC now owns 2,606,016 shares of the biotechnology company's stock worth $70,170,000 after purchasing an additional 1,656,111 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Rocket Pharmaceuticals by 11.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,943,160 shares of the biotechnology company's stock worth $79,290,000 after buying an additional 314,086 shares during the period. First Turn Management LLC increased its stake in shares of Rocket Pharmaceuticals by 123.6% in the 2nd quarter. First Turn Management LLC now owns 560,989 shares of the biotechnology company's stock valued at $12,078,000 after acquiring an additional 310,119 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Rocket Pharmaceuticals in the 2nd quarter valued at approximately $2,144,000. Finally, Harbor Capital Advisors Inc. boosted its stake in Rocket Pharmaceuticals by 73.5% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 168,506 shares of the biotechnology company's stock worth $3,112,000 after acquiring an additional 71,372 shares during the last quarter. 98.39% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on RCKT shares. Chardan Capital reissued a "buy" rating and set a $62.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th. Needham & Company LLC reissued a "buy" rating and issued a $52.00 target price on shares of Rocket Pharmaceuticals in a research note on Friday. Canaccord Genuity Group reaffirmed a "buy" rating and set a $38.00 price target on shares of Rocket Pharmaceuticals in a research report on Monday, September 30th. Scotiabank assumed coverage on Rocket Pharmaceuticals in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $50.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their target price on shares of Rocket Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $51.75.

Rocket Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ RCKT traded up $0.20 during midday trading on Friday, reaching $17.45. The company's stock had a trading volume of 902,588 shares, compared to its average volume of 661,944. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $15.98 and a fifty-two week high of $32.53. The stock has a 50 day simple moving average of $18.04 and a 200-day simple moving average of $20.40. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -6.35 and a beta of 1.09. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.05.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.